HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
Conditions
Keywords
HER2-positive, solid tumours
Brief summary
HER2+ breast and gastric cancer patients' survival is significantly improved by trastuzumab alone or in combination with chemotherapy. However, many patients remain uncured and develop resistance to trastuzumab resulting in relapse or progression of the disease. BI-1607, a human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) targets CD32b (Fc Gamma Receptor IIB), it is intended to enhance the efficacy and overcome resistance to existing cancer treatments such as trastuzumab. This is a Phase 1/2a, first-in-human, open-label, multicenter, dose-escalation, consecutive-cohort study of BI-1607 in combination with trastuzumab in subjects with HER2+ advanced solid tumors whose tumor has progressed after standard therapy.
Detailed description
This is a Phase 1/2a, first-in-human, open-label, multicenter, dose-escalation, consecutive-cohort study of BI-1607 in combination with trastuzumab in subjects with HER2+ advanced solid tumors whose tumor has progressed after standard therapy. The Phase 1 part of the trial is a dose escalation study of BI-1607 combined with trastuzumab in HER2+ advanced or metastatic solid tumors, the aim is to assess safety and tolerability and to determine the recommended phase II dose of BI-1607 in combination with trastuzumab. The selected dose of BI-1607 will be studied in a subsequent Phase 2a part of the trial along with trastuzumab in 2 open-label, expansion cohorts of 15 evaluable subjects each. The first cohort will enroll subjects with locally advanced or metastatic HER2+ breast cancer, and the second will recruit subjects with HER2+ metastatic gastric or gastroesophageal junction adenocarcinoma. The aim of the phase 2a is to collect additional safety data to further support the recommended dose, and to detect early signs of clinical activity.
Interventions
DRUGBI-1607
administered at different doses in Phase I by intravenous infusions every 3 weeks.
DRUGTrastuzumab
administered at 8mg/kg for the first infusion and at 6mg/kg in subsequent infusions by intravenous infusions every 3 weeks.
Sponsors
BioInvent International AB
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a Phase 1/2a, FIH, open-label, multicenter, dose-escalation, consecutive-cohort study of BI-1607 in combination with trastuzumab. The study will consist of 2 Phases: * Phase 1, the dose-escalation part of the study, the aim of which is to assess safety and tolerability and to determine the RP2D of BI-1607 in combination with trastuzumab in subjects with HER2+ advanced solid tumors. * Phase 2a, comprising of 2 separate expansion cohorts treated at the RP2D of BI-1607 in combination with trastuzumab in subjects with locally advanced or metastatic HER2+ breast cancer and subjects with HER2+ metastatic gastric or gastroesophageal junction adenocarcinoma. The aim of Phase 2a is to collect additional safety data to further support RP2D, and to detect early signs of clinical activity.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Main Inclusion Criteria: * Is willing and able to provide written informed consent for the trial. * Is ≥18 years of age on day of signing informed consent. * Has received standard of care or is intolerant to standard of care antineoplastic therapy. Subjects who are intolerant to trastuzumab cannot be enrolled in the study. * Has at least 1 measurable disease lesion as defined by RECIST v1.1 criteria. * Has a locally confirmed HER2+ tumor. * Must have progressive disease after the last line of treatment. In addition, subjects must have received the following previous lines of treatment: 1. Prior lines of treatment including trastuzumab and chemotherapy. 2. At least one prior line of treatment with an antibody-drug conjugate (ADC) (eg, trastuzumab-emtansine \[TDM-1, or trastuzumab-deruxtecan\]). Main
Exclusion criteria
* Needs doses of prednisolone \>10 mg daily (or equipotent doses of other corticosteroids) while on the trial other than as premedication. * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. * Has cardiac or renal amyloid light-chain amyloidosis. * Has had clinically significant lung disease requiring systemic corticosteroid treatment within the last 6 months of enrollment. * Has an active, known, or suspected autoimmune disease. * Is at high medical risk because of nonmalignant systemic disease including severe active infections on treatment with antibiotics, antifungals, or antivirals. * Has presence of chronic graft versus host disease. * Has had an allogenic tissue/solid organ transplant. * Has uncontrolled or significant cardiovascular disease. * Has a known additional malignancy of another type, except for adequately treated cone-biopsied carcinoma in situ (eg, breast carcinoma, cervical cancer in situ), adequately controlled superficial bladder cancer, and basal or squamous cell carcinoma of the skin. * Has a diagnosis of primary or acquired immunodeficiency disorder or is taking any other form of immunosuppressive therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the safety and tolerability profile of BI-1607 in combination with trastuzumab | End of treatment visit or 30 days after last dose of study drug. | Adverse events (AEs) and serious adverse events (SAEs) (graded according to the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] v5.0) and their causality in relation to BI-1607 or to the combination with trastuzumab |
| Identify Dose limiting toxicities, determine the maximum tolerate dose of BI-1607 and propose a recommended Phase 2 dose (RP2D) for evaluation of BI-1607 in combination with trastuzumab. | 22 days | Occurrence of DLTs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the immunogenicity of BI-1607 when administered in combination with trastuzumab | 90 days after the last dose of BI-1607 | Antidrug antibody response to BI-1607 in blood serum |
| Assessment of the pharmacokinetic (PK) profile of BI-1607 when administered every 3 weeks in combination with trastuzumab | 90 days after the last dose of BI-1607 | The PK parameters will include area under the serum concentration-time curve, maximum concentration, time to maximum concentration, and terminal half-life |
| Assessment of the CD32b receptor occupancy (RO) of BI-1607 on B cells when administered in combination with trastuzumab | 30 days after the last dose of BI-1607 | RO on circulating B lymphocytes |
| Assessment of the possible antitumor activity of BI-1607 in combination with trastuzumab | 1 year after the last treatment | Best tumor response, objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, progression-free survival (PFS), time to response, duration of response (DOR) and OS |
Other
| Measure | Time frame | Description |
|---|---|---|
| Exploratory: investigate the genetic background of subjects with respect to FcgammaR isoforms and explore a potential correlation of the genetic background with clinical responses | 1 day | Determination of Fcgamma receptor isoforms using nucleotide-based assays on genetic material extracted from whole blood |
| Exploratory: investigate expression levels of Fc receptors, and other immunological markers on immune cells infiltrating the tumor | 1 day | Expression levels of Fc receptors (eg, CD32b) and other markers of immunological activity using immunohistochemistry (IHC) and/or nucleotide-based assays using tissue samples |
| Exploratory: explore any exposure-response and/or exposure-safety relationship between BI-1607 serum concentrations and clinical outcome | 1 day | Correlation of BI-1607 PK and antitumor activity measures, as well as to safety measures of interest |
Countries
Germany, Spain, United Kingdom
Outcome results
None listed